- ImmunityBio and NantKwest have merged, creating a juggernaut pre-clinical and clinical pipeline. The share price has been weak since the merger, however I remain bullish at these prices.
- The company has an impressive COVID-19 vaccine candidate that could be best-in-class and possibly help end the pandemic.
- I discuss some of the problems were are facing with the current lot of vaccines and how ImmunityBio's vaccine could address these issues.
- The recent sell-off has forced me to update my IBRX strategy.
For further details see:
ImmunityBio: Remaining Bullish As Global Vaccine Apparatus Continues To Misfire